1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance

Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance

  • January 2018
  • 73 pages
  • ID: 5336529
  • Format: PDF
  • GlobalData
Up to $4197 off Until May 31st 2020

Summary

Table of Contents

Search Inside

Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance

Summary
Antibacterial resistance is currently believed to be responsible for over 700,000 deaths each year. As antibiotic resistance increases, due to the overuse and misuse of antibiotics, the number of avoidable deaths is expected to increase, with one study predicting there will be 10 million deaths caused by bacteria resistant to antibiotics in 2050.

There are several techniques being utilized to combat the spread of antibiotic resistance, which range from combining antibiotics to increase efficacy to reducing the use antibiotics in both humans and livestock.

However, significantly reducing the number of deaths caused by antibacterial resistance will require the development of new antibacterials that target infections caused by the most deadly and antibiotic resistant bacteria while acting on targets not currently utilized by marketed products in order to avoid cross resistance.

Without the development of innovate antibacterial products the emergence and spread of antibiotic resistance will not only increase the number of avoidable deaths caused by the infection itself, it also has the potential to increase the risks associated with surgery, while putting additional pressure on already stretched healthcare providers, as treating drug-resistant infections is considerably more expensive than treating drug-susceptible infections.

This report examines the entire antibacterial therapy area with a particular focus on four key indications, methicillin resistant staphylococcus aureus (MRSA), sepsis, pneumonia and tuberculosis, which were selected due to their pipeline size, prevalence and level of unmet need.

Scope
- The antibacterial pipeline is large, with 1,634 products in active development. Does current pipeline innovation hold the potential to affect the future antibacterial market?
- The four key indications in the antibacterial pipeline are tuberculosis, pneumonia, MRSA and sepsis. How does the composition of each pipeline compare both in terms of first-in-class and non-first-in-class innovation.
- There are 234 first-in-class products in the antibacterial pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?
- Analysis of strategic consolidations and deals revealed a high level of activity between 2006 and 2017.
- A significant number of first-in-class products have been identified with no prior involvement in deals. How does deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy
- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
- Visualize the composition of the antibacterial therapeutics market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the antibacterial pipeline and stratify by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, human first-in-class targets have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($6995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on